Provexis PLC - Purchase of Fruitflow® II SD & royalty payment
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the
Provexis plc
('Provexis' or the 'Company')
Purchase of Fruitflow® II SD from dsm-firmenich,
payment of royalty to dsm-firmenich and issue of equity
Total voting rights
Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to announce it has agreed to purchase a further batch of Fruitflow II SD ('Fruitflow') inventory from dsm-firmenich, to satisfy increasing demand for Fruitflow.
Under a Transfer of Business Agreement between Provexis and dsm-firmenich, which Provexis announced on
Provexis and dsm-firmenich have agreed that the estimated royalty for the two years ended
The inventory purchase and two-year royalty payment total
The Company and dsm-firmenich agreed a valuation of
The 82,945,984 New Provexis Shares were valued at
An application has been made to the London Stock Exchange for the 82,945,984 New Provexis Shares to be admitted to trading on AIM. It is expected that admission will become effective and that trading in the New Provexis Shares will commence on or around
Following Admission, the Company's enlarged issued share capital will comprise 2,345,891,239 ordinary shares with voting rights. The Company does not hold any shares in treasury. This figure of 2,345,891,239 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
It has been agreed with dsm-firmenich that the 82,945,984 New Provexis Shares will be issued to DSM Venturing BV, a significant existing shareholder in Provexis. Following the issue of the 82,945,984 New Provexis Shares, DSM Venturing BV will hold 256,743,074 shares, which will be 10.94% of the Company's enlarged issued share capital.
'We are delighted to have completed this further purchase of Fruitflow inventory from dsm-firmenich, along with payment in new shares of the estimated royalty due to dsm-firmenich for the two years ended
The further purchase of Fruitflow inventory announced today has been made to satisfy an increasing demand from customers of Provexis for Fruitflow, and it reflects the positive momentum that Provexis has enjoyed since initiating the process to transfer customers from dsm-firmenich to the Company in
For further information please contact:
|
Provexis plc
|
Tel: 07490 391888 |
|
Allenby Capital Limited (Nominated Adviser and Broker) |
Tel: 020 3328 5656
|
Notes for editors
About Provexis plc
AIM quoted Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.
Fruitflow is a natural, breakthrough ingredient that helps with platelet aggregation. This helps promote normal blood flow and circulation, which in turn benefits cardiovascular health. Fruitflow helps the platelets to circulate freely and smoothly throughout your blood, without sticking to one another or to the blood vessels themselves. Freely flowing blood helps reduce stress on your cardiovascular system.
Fruitflow is a highly concentrated form of bioactives which is lycopene-free and contains over 30 known anti-platelet compounds. Published clinical studies have shown that Fruitflow works to maintain healthy blood flow in a similar way to 75mg aspirin but with a milder and reversible action; Fruitflow has a similar antiplatelet effect to a single dose of aspirin - but when taken daily, it has none of aspirin's side effects.
The science behind Fruitflow has been validated by leading peer review publications and regulatory authorities. Fruitflow is the only natural antiplatelet to have a health claim approved by the European Food Safety Authority, stating that 150mg of Fruitflow 'helps maintain normal platelet aggregation, which contributes to healthy blood flow'.
Fruitflow has a number of specific health benefits which have been reflected in separate patent filings for the use of Fruitflow in:
· mitigating exercise-induced inflammation;
· managing blood pressure;
· protecting against the adverse effects of air pollution on the body's cardiovascular system. Laboratory work has shown that Fruitflow can reduce the platelet activation caused by airborne particulate matter, such as that from diesel emissions, by approximately one third; and
· conferring health benefits in modulating the gut microbiome of humans, to include a reduction in TMAO, following the completion of a successful human study which is further detailed here www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html.
Provexis sells a high quality dietary supplement product containing Fruitflow and Omega-3 from its website www.fruitflowplus.com on a mail order basis. The product is also available to purchase from Amazon.co.uk.
Provexis has been working with BYHEALTH, a circa
The Chinese regulatory system for functional health food ingredients, such as Fruitflow, is governed by the State Administration for Market Regulation (the 'SAMR') and it is based on a defined list of permitted health function claims which brand owners are permitted to use on product labels.
In
The significance of these major developments for Fruitflow in
Provexis was founded in 1999 and is headquartered in
For further information, please visit www.provexis.com and www.fruitflowplus.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE